Biological Products, (No Diagnostic Substances) · DE · CIK 1737953
Replimune develops oncolytic immunotherapies to activate the immune system against cancer
Comparable business profile · signals at a glance
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
In the 90 days to Dec 9, 2025: 4 sold $258K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 9, 2025 | Dhingra KapilDirector | Sell | 3,169 | $10.40 | $33K |
| Dec 2, 2025 | Patel SushilChief Executive Officer | Sell | 10,000 | $11.13 | $111K |
| Nov 17, 2025 | Xynos KonstantinosChief Medical Officer | Sell | 7,248 | $9.10 | $66K |
| Nov 17, 2025 | Sarchi ChristopherChief Commercial Officer | Sell | 5,208 | $9.10 | $47K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.